A159 RISK OF TOTAL METACHRONOUS ADVANCED NEOPLASIA IN PATIENTS WITH SERRATED LESIONS AND INFLAMMATORY BOWEL DISEASE

Autor: E Medawar, R Djinbachian, I Popescu Crainic, P Lakatos, A Barkun, E -J Bernard, D von Renteln
Rok vydání: 2023
Zdroj: Journal of the Canadian Association of Gastroenterology. 6:7-8
ISSN: 2515-2092
2515-2084
DOI: 10.1093/jcag/gwac036.159
Popis: Background The risk of total metachronous advanced neoplasia (TMAN) in patients with serrated lesions (SL) and IBD is unknown. It is also unclear whether colonic inflammation in IBD contributes to serrated neoplasia. Purpose Study aim was to compare the risk of TMAN at surveillance colonoscopies in patients with SL and IBD to patients with SL without IBD. We also sought to compare IBD severity in patients with IBD and SL in a colonic area involved with IBD (SL-IA) to patients with IBD and SL in an uninvolved area (SL-UA). Method A cohort study was conducted. Through pathology database search, we identified 2428 patients with endoscopically resected SL, defined as sessile serrated lesion (SSL), traditional serrated adenoma (TSA) or IBD and serrated epithelial change (SEC), between 2010 and 2019 at the University of Montreal Hospital Center. We included patients aged 45-75 without polyposis syndromes and excluded patients with a history of CRC, first surveillance Result(s) In the metachronous outcomes analysis, 440 patients with SL (mean age 61.8 y., 51.6% male, 424 SSL, 16 TSA) were eligible, and 37 with SL and IBD were eligible (mean age 60.9 y., 54.1% male, 30 SSL, 6 SEC, 1 TSA). Compared to patients without IBD, IBD patients were less likely to have synchronous adenomas (16.2% vs 41.6%, p0.05), and similar maximal therapeutic maintenance steps (p>0.05), as well as Mayo/SES-CD scores, serum C-reactive protein, hemoglobin, and albumin, and fecal calprotectin values at index and last colonoscopy (p>0.05). Conclusion(s) Patients with SL and IBD are not at higher risk of total metachronous advanced neoplasia than patients with SL and no IBD. SLs in IBD should be considered sporadic and undergo endoscopic resection and follow-up similar to non-IBD patients. Please acknowledge all funding agencies by checking the applicable boxes below CIHR, Other Please indicate your source of funding; Fonds de Recherche du Québec en Santé Disclosure of Interest None Declared
Databáze: OpenAIRE
Externí odkaz: